4 Healthcare Stock Stories to Kick Off the Trading Week

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): Closing price $28.65

Isis announced Monday that patients who were treated with ISIS-CRP achieved rapid, dose-dependent mean reductions of as much as 67 percent in C-reactive protein, during Phase 2 evaluations in patients who have rheumatoid arthritis. Patients treated with ISIS-CRP indicated improvements in signs and symptoms of RA, but these improvements were not statistically significant versus those observed in patients in the placebo group, which showed a higher-than-expected response in both symptom score and CRP reduction. A Phase 2 study of ISIS-CRP in patients suffering with atrial fibrillation is presently ongoing, with data expected in the first half of 2014.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ISIS-08052013

Galectin Therapeutics (NASDAQ:GALT),: Closing price $5.81

On Monday, Galectin reported new preclinical data on the efficacy of anti-galectin therapy for lung fibrosis, employing a model that simulates the human disease idiopathic pulmonary fibrosis. In this model, treatment with GR-MD-02 indicated a robust effect in lowering lung fibrosis, with a somewhat smaller effect from GM-CT-01. The firm develops therapeutics that target galectin proteins to treat fibrosis and cancer.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

galt-08052013

Enzo Biochem Inc. (NYSE:ENZ): Closing price $2.53

Enzo said Monday that a Federal Court Judge in New Haven has upheld the jury verdict issued in November of last year, which awarded Enzo $48.6 million in direct infringement damages as a result of Applera Corp., now Life Technologies, Inc. (NASDAQ:LIFE), having infringed Enzo’s patent that protects pioneering technologies connected with compounds used in DNA sequencing systems to read the genetic code. The judge’s ruling gives a green light for Enzo’s recovery of prejudgment interest on the damages award, which should surpass $25 million in addition to the judgment.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

enz-08052013

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP): Closing price $4.85

Synergy has announced that it has finalized an End-of-Phase 2 meeting with the FDA on its drug plecanatide for the treatment of chronic idiopathic constipation. At that meeting, an accord was reached regarding the clinical development plan. A pivotal phase-3 program studying the safety and efficacy of plecanatide in CIC patients will be initiated in the fourth quarter. Agreement was reached with the FDA on duration, design, size, and primary and secondary efficacy endpoints for the pivotal phase 3 studies.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

sgyp-08052013

Don’t Miss: Cable Companies Beware: Google and Netlix are Coming for You.

More Articles About:    

More from The Cheat Sheet